OUR STRATEGY
Download the pdf and discover our projects
THE PRODUCT
Previous
Next
THE MARKET
Western Europe and USA
- Lung, colon, ovary cancers new cases/ year: 700.000
- Tumors expressing Trop-2: 500.000
- Health services reimbursements: 30.000 €/ patient
Target total sales: 10 billion €/ year
Example: Herceptin 7 billion € / year
COMPETITORS
Immunomedics generated the humanized RS7 antibody conjugated to SN38 (Sacituzumab Govitecan, IMMU-132). This ADC, however, is based on outdated technologies (reduction of disulfide bridges). Similar technologies have been recently implemented by Daiichi Sankyo with the anti-Trop-2 ADC DS-1062, currently in lung cancer experimentation, obtaining corresponding results. Innovative conjugation technologies and the use of toxins of very high power can allow the ADC anti-Trop-2 Hu2g10 to become "best in class".
KEY RESOURCES
- Leadership in the field of Trop-2 research
- Unique know-how on the molecule
- Proprietary anti-Trop-2 antibodies
- Major collaborators network
- Two granted strategic PCT (WO 2010/035304; WO 2010/089782); two pending PCT
- main PCT:
- antibodies & lines of hybridomas
- production strategy → synergy of use
- Efficacy in preclinical models
- Regulatory activity planning